Bora Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Bobby Sheng

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	9.8yrs
Eigentum des Geschäftsführers	6.9%
Durchschnittliche Amtszeit des Managements	6.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.1yrs

Jüngste Management Updates

Recent updates

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Jun 13

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Apr 10

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Apr 08

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Mar 14

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Apr 30

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Mar 17

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Feb 17

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Jan 27

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Jan 19

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Dec 29

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Dec 09

Geschäftsführer

Bobby Sheng

9.8yrs

Amtszeit

Mr. Pao-Shi Sheng, also known as Bobby, serves as Chairman of the Board at SunWay Biotech Co. LTD. since 2024. He Founder of Earth 88 and serves as its Chief Executive Officer.He serves as an Independent...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pao-Shi Sheng	Chairman	no data	keine Daten	6.86% NT$ 5.7b
Alice Wang	CFO of HQ & APAC	11.4yrs	keine Daten	keine Daten
Ellen Chen	Corporate Human Resource Director	2.4yrs	keine Daten	keine Daten
Shih-Min Chen	VP & Director	11.2yrs	keine Daten	1.11% NT$ 922.5m
Sally Langa	Senior VP of Marketing and Sales - CDMO Business	no data	keine Daten	keine Daten
Marcel Vieno	CFO of North America	no data	keine Daten	keine Daten
Tom Chang	Senior Vice President of Taiwan Site Operations	1.4yrs	keine Daten	keine Daten
Xiu-Rong Zhang	Deputy General Manager	no data	keine Daten	0.010% NT$ 8.4m
Zhen-Tang Zhang	Deputy General Manager	no data	keine Daten	0.097% NT$ 81.0m

6.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: Das Managementteam von 6472 ist erfahren und erfahren (durchschnittliche Amtszeit: 6.7 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pao-Shi Sheng	Chairman	9.8yrs	keine Daten	6.86% NT$ 5.7b
Shih-Min Chen	VP & Director	9.8yrs	keine Daten	1.11% NT$ 922.5m
Jui-Yi Lin	Independent Director	9.2yrs	keine Daten	keine Daten
Shang-Hung Shen	Director	9.8yrs	keine Daten	keine Daten
Kuan-Pai Chen	Director	5yrs	keine Daten	keine Daten
Ming-Jung Lai	Independent Director	7yrs	keine Daten	keine Daten
Yi-Chin Lee	Independent Director	7yrs	keine Daten	0.032% NT$ 26.8m
Hsin-I Lin	Independent Director	less than a year	keine Daten	0.00099% NT$ 825.7k

8.1yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: 6472Die Vorstandsmitglieder gelten als erfahren (8 Jahre durchschnittliche Amtszeit).

Bora Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Bora Pharmaceuticals Co., LTD., Annual General Meeting, May 27, 2024

Bora Pharmaceuticals Co., Ltd. Elects Lin Hsin-I as Independent Director

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

First quarter 2024 earnings: EPS exceeds analyst expectations

Bora Pharmaceuticals Co., LTD. to Report Q1, 2024 Results on May 14, 2024

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Investor sentiment improves as stock rises 18%

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Consensus revenue estimates increase by 11%

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Bora Pharmaceuticals Co., LTD., Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS misses analyst expectations

Price target increased by 17% to NT$827

Price target increased by 7.7% to NT$713

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 11%

SunWay Biotech Co., LTD. (TPEX:1271) agreed to acquire Bora Health Inc from Bora Pharmaceuticals Co., LTD. (TPEX:6472).

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 15%

Upcoming dividend of NT$8.00 per share at 1.0% yield

Bora Pharmaceuticals Co., Ltd. Elects Lin Hsin-I as Independent Director

Bora Pharmaceuticals Co., LTD. to Report Q1, 2023 Results on May 17, 2023

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates increase by 18%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 27%

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 31%

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Price target increased to NT$231

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.50 per share

Bora Pharmaceuticals Co., LTD. Announces Common Stock Cash Dividend, Payable on August 2, 2022

Bora Pharmaceuticals Co., LTD. announced that it has received TWD 800 million in funding

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target increased to NT$302

Third quarter 2021 earnings released: EPS NT$2.02 (vs NT$0.82 in 3Q 2020)

Price target increased to NT$276

Investor sentiment deteriorated over the past week

Upcoming dividend of NT$2.00 per share

Second quarter 2021 earnings released: EPS NT$2.54 (vs NT$0.80 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$6.18 (vs NT$0.84 in 1Q 2020)

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Investor sentiment improved over the past week

Consensus revenue estimates increase to NT$5.23b

Price target increased to NT$219

Full year 2020 earnings released: EPS NT$10.76 (vs NT$6.08 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Investor sentiment improved over the past week

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

New 90-day low: NT$157

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Investor sentiment deteriorated over the past week

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Investor sentiment improved over the past week

New 90-day high: NT$199

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Price target raised to NT$191

New 90-day high: NT$194